The company has announced plans to introduce comprehensive at-home lab tests, leveraging the acquisition of Trybe Labs, which could enhance service personalization and attract new customers. Additionally, expansion into markets such as Canada and Europe (through the acquisition of Zava) opens new revenue growth opportunities. The company demonstrates continuous financial improvement, including record profitability and a 111% revenue increase since reaching its ATH (All-Time High) in February 2025, which builds investor confidence.
The chart analysis of Hims & Hers Health, Inc. (NYSE: HIMS) indicates a clear upward trend in the recent period. The current price is approximately 49.38 USD. Based on historical data and visible momentum, there is potential for a growth of about 50%, which could bring the price to around 75 USD. Key support is located around 45 USD, while resistance may be tested in the 55-60 USD range before further upward movement. It is recommended to monitor volume and key technical levels to confirm the continuation of the trend.
Potential TP: 75 $
The chart analysis of Hims & Hers Health, Inc. (NYSE: HIMS) indicates a clear upward trend in the recent period. The current price is approximately 49.38 USD. Based on historical data and visible momentum, there is potential for a growth of about 50%, which could bring the price to around 75 USD. Key support is located around 45 USD, while resistance may be tested in the 55-60 USD range before further upward movement. It is recommended to monitor volume and key technical levels to confirm the continuation of the trend.
Potential TP: 75 $
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.